MedTrace Logo

Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19

NCT04922788 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 13006

Last updated 2025-03-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, immunogenicity, and efficacy of Nanocovax vaccine in volunteer subjects 18 years of age and older.

Conditions

Interventions

BIOLOGICAL

Nanocovax

Recombinant Protein spike (s) SARS-CoV-2 and 0,5 mg Aluminum adjuvant

BIOLOGICAL

Placebo

0,5 mg Aluminum adjuvant

Sponsors & Collaborators

  • Nanogen Pharmaceutical Biotechnology Joint Stock Company

    lead INDUSTRY

Principal Investigators

  • Thuy Nguyen, MD · Medical Affairs Department

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-07
Primary Completion
2022-07-20
Completion
2022-07-20

Countries

  • Vietnam

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04922788 on ClinicalTrials.gov